Please assess the completion status of the following clinical trial:

Trial Title: Metformin to Treat Obesity in Children With Insulin Resistance

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: QUADRUPLE
- Phase: PHASE2
- Number of Arms: 2.0

Eligibility Criteria:
* INCLUSION CRITERIA:~Good general health.~Age greater than or equal to 6 and less than 13 years.~Pre-pubertal or having at most early puberty (breast Tanner I, II or III for girls, testes size less than or equal to 8 mL for boys).~Hyperinsulinemia, defined as fasting insulin concentration greater than or equal to 15 mIU/mL. The insulin level must be greater than or equal to 15 at either the NIH Clinical Center lab or the NIDDK lab at PIMC in Phoenix.~Obesity, defined as body mass index greater than or equal to 95th percentile determined by NHANES I age and sex specific data.~Subjects must have fasting plasma glucose less than 126 mg/dl~Subjects must have glycosylated hemoglobin (HgbA1C) of less than or equal to 6.5%.~Females who begin menstruating (or who are at risk for pregnancy) during the study must have a negative pregnancy test and must use an effective method of contraception if they are engaging in sexual intercourse.~EXCLUSION CRITERIA:~Baseline creatinine greater or equal to 1.0 mg/dl.~Significant cardiac or pulmonary disease likely to or resulting in hypoxia or decreased perfusion.~Hepatic disease with elevated liver function tests (ALT or AST) greater than or equal to 1.5 the upper limits of normal.~An alcohol history concerning for development of hepatic toxicity.~Pregnancy.~Evidence for Type 2 diabetes, including fasting plasma glucose greater than or equal to 126 mg/dl or HgbA1C greater than 6.5%.~Weight loss of greater than 2% of bodyweight within the past 6 months.~Presence of other endocrinologic disorders leading to obesity (e.g. Cushing's Syndrome).~Individuals who have, or whose parent or guardians have current substance abuse or a psychiatric disorder or other condition that, in the opinion of the investigators, would impede competence or compliance or possibly hinder completion of the study.~Recent use (within six months) of anorexiant medications.~Individuals receiving medical treatment other than diet for hypertension or dyslipidemia.~Individuals with evidence of precocious puberty.

- Gender: ALL
- Minimum Age: 6 Years
- Maximum Age: 12 Years
- Healthy Volunteers: f

Study Arms:
- 1 - Metformin HCL (Type: ACTIVE_COMPARATOR): Subjects receive metformin plus a weight loss program
- 2 - Placebo (Type: PLACEBO_COMPARATOR): Subjects receive placebo plus a weight loss program

Based on this trial design, predict the completion outcome and termination type (if applicable).